Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS)

References

• Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–257.
   PubMed Web of Science ®Google Scholar
• Cory S. Regulation of lymphocyte survival by the BCL-2 gene family. Annu Rev Immunol. 1995;13:513–543.
   PubMed Web of Science ®Google Scholar
• Hengartner H, Odermat B, Schneider R, et al. Deletion of self-reactive T cells before entry into the thymus medulla. Nature. 1988;336(6197):388–390.
   PubMed Web of Science ®Google Scholar
• Kisielow P, Blüthmann H, Staerz UD, et al. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4 + 8+ thymocytes. Nature. 1988;333(6175):742–746.
   PubMed Web of Science ®Google Scholar
• Palmer E. Negative selection-clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol. 2003;3(5):383–391.
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.
   PubMed Web of Science ®Google Scholar
• Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science. 1990;248(4961):1349–1356.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Turley S, Mellman I, et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191(3):411–416.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–787.
   PubMed Web of Science ®Google Scholar
• Lenardo M, Chan FKM, Hornung F, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999;17:221–253.
   PubMed Web of Science ®Google Scholar
• Tanchot C, Rosado MM, Agenes F, et al. Lymphocyte homeostasis. Semin Immunol. 1997;9(6):331–337.
   PubMedGoogle Scholar
• Anel A, Gallego-Lleyda A, de Miguel D, et al. Role of exosomes in the regulation of T-cell mediated immune responses and in autoimmune disease. Cells. 2019;8(2):154.
   Web of Science ®Google Scholar
• Bosque A, Pardo J, Martínez-Lorenzo MJ, et al. Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c- FLIP, Bim, or Bcl-x isoform expression. J Leukoc Biol. 2005;77(4):568–578.
   PubMed Web of Science ®Google Scholar
• Bosque A, Marzo I, Naval J, et al. Apoptosis by IL-2 deprivation in human CD8+ T cell blasts predominates over death receptor ligation, requires Bim expression and is associated with Mcl-1 loss. Mol Immunol. 2007;44(6):1446–1453.
   PubMed Web of Science ®Google Scholar
• Cory S, Adams JM. The BCL2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–656.
   PubMed Web of Science ®Google Scholar
• Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020;21(2):85–100.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305–1308.
   PubMed Web of Science ®Google Scholar
• Krammer PH. CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol. 1999;71:163–210.
   PubMedGoogle Scholar
• Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355–365.
   PubMed Web of Science ®Google Scholar
• Cho SG, Choi EJ. Apoptotic signaling pathways: caspases and stress-activated protein kinases. J Biochem Mol Biol. 2002;35(1):24–27.
   PubMedGoogle Scholar
• Nagata S. Apoptosis and clearance of apoptotic cells. Annu Rev Immunol. 2018;36:489–517.
   PubMed Web of Science ®Google Scholar
• Li KP, Shanmuganad S, Carroll K, et al. Dying to protect: cell death and the control of T-cell homeostasis. Immunol Rev. 2017;277(1):21–43.
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356(6367):314–317.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand. Cell. 1994;76(6):969–976.
   PubMed Web of Science ®Google Scholar
• Nagata S, Golstein P. The Fas death factor. Science. 1995;267(5203):1449–1456.
   PubMed Web of Science ®Google Scholar
• Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995;16(1):39–43.
   PubMedGoogle Scholar
• Wilber A, O'Connor TP, Lu ML, et al. Dnase1l3 deficiency in lupus-prone MRL and NZB/W F1 mice. Clin Exp Immunol. 2003;134(1):46–52.
   PubMed Web of Science ®Google Scholar
• Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967;70(6):891–899.
   PubMed Web of Science ®Google Scholar
• Sneller MC, Straus SE, Jaffe ES, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992;90(2):334–341.
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268(5215):1347–1349.
   PubMed Web of Science ®Google Scholar
• Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935–946.
   PubMed Web of Science ®Google Scholar
• Drappa J, Vaishnaw AK, Sullivan KE, et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996;335(22):1643–1649.
   PubMed Web of Science ®Google Scholar
• Neven B, Magerus-Chatinet A, Florkin B, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118(18):4798–4807.
   PubMed Web of Science ®Google Scholar
• Price S, Shaw PA, Seitz A, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123(13):1989–1999.
   PubMed Web of Science ®Google Scholar
• Bosque A, Pardo J, Martínez-Lorenzo MJ, et al. Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL. Eur J Immunol. 2005;35(6):1812–1821.
   PubMed Web of Science ®Google Scholar
• Bosque A, Aguiló JI, del Rey M, et al. Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes. J Leukoc Biol. 2008;84(2):488–498.
   PubMed Web of Science ®Google Scholar
• Daszkiewicz L, Vázquez-Mateo C, Rackov G, et al. Distinct p21 requirements for regulating normal and self-reactive T cells through IFN-γ production. Sci Rep. 2015;5(1):7691–7614.
   PubMedGoogle Scholar
• Balomenos D, Shokri R, Daszkiewicz L, et al. On how fas apoptosis-independent pathways drive T cell hyperproliferation and lymphadenopathy in lpr mice. Front Immunol. 2017. DOI:https://doi.org/10.3389/fimmu.2017.00237
   Google Scholar
• Bosque A, Aguiló JI, Alava MA, et al. The induction of Bim expression in human T-cell blasts is dependent on nonapoptotic Fas/CD95 signaling. Blood. 2007;109(4):1627–1635.
   PubMed Web of Science ®Google Scholar
• Rossin A, Miloro G, Hueber AO. TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity. Cancers. 2019;11(5):639.
   Web of Science ®Google Scholar
• Bleesing JJH, Brown MR, Novicio C, et al. A composite picture of TcR alpha/beta(+) CD4(-)CD8(-) T Cells (alpha/beta-DNTCs) in humans with autoimmune lymphoproliferative syndrome. Clin Immunol. 2002;104(1):21–30.
   PubMed Web of Science ®Google Scholar
• Bristeau-Leprince A, Mateo V, Lim A, et al. Human TCR alpha/beta + CD4-CD8- double-negative T cells in patients with autoimmune lymphoproliferative syndrome express restricted Vbeta TCR diversity and are clonally related to CD8+ T cells. J Immunol. 2008;181(1):440–448.
   PubMed Web of Science ®Google Scholar
• Ibegbu CC, Xu Y-X, Harris W, et al. Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T lymphocytes during active, latent, and resolved infection and its relation with CD57. J Immunol. 2005;174(10):6088–6094.
   PubMed Web of Science ®Google Scholar
• Völkl S, Rensing-Ehl A, Allgäuer A, et al. Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood. 2016;128(2):227–238.
   PubMed Web of Science ®Google Scholar
• Rensing-Ehl A, Völkl S, Speckmann C, et al. Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency. Blood. 2014;124(6):851–860.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Obzut DA, Axsom K, Choi JK, et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. 2006;108(6):1965–1971.
   PubMed Web of Science ®Google Scholar
• Bride KL, Vincent T, Smith-Whitley K, Lambert MP, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-Institutional trial. Blood. 2016;127(1):17–28.
   PubMed Web of Science ®Google Scholar
• Teachey D, Bride K. Autoimmune lymphoproliferative syndrome: more than a FAScinating disease. F1000Res. 2017;6:1928.
   PubMedGoogle Scholar
• Klemann C, Esquivel M, Magerus-Chatinet A, et al. Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome. Haematologica. 2017;102(2):e52–e56.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4 + CD25 + FoxP3+ regulatory T cells . Blood. 2005;105(12):4743–4748.
   PubMed Web of Science ®Google Scholar
• Mazerolles F, Stolzenberg MC, Pelle O, et al. Autoimmune lymphoproliferative syndrome-fas patients have an abnormal regulatory T cell (Treg) phenotype but display normal natural Treg-suppressive function on T cell proliferation. Front Immunol. 2018. DOI:https://doi.org/10.3389/fimmu.2018.00718
   Google Scholar
• Lopatin U, Yao X, Williams RK, et al. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood. 2001;97(10):3161–3170.
   PubMed Web of Science ®Google Scholar
• Neven B, Bruneau J, Stolzenberg MC, et al. Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. Blood. 2014;124(10):1597–1609.
   PubMed Web of Science ®Google Scholar
• Janda A, Schwarz K, Van Der Burg M, et al. Disturbed B-lymphocyte selection in autoimmune lymphoproliferative syndrome. Blood. 2016;127(18):2193–2202.
   PubMed Web of Science ®Google Scholar
• Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.
   PubMed Web of Science ®Google Scholar
• Bousfiha A, Jeddane L, Picard C, et al. Human inborn errors of immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol. 2020;40(1):66–81.
   PubMed Web of Science ®Google Scholar
• Van Der Burg M, De Groot R, Comans-Bitter WM, et al. Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant or recessive disease? Pediatr Res. 2000;47(3):336–343.
   PubMed Web of Science ®Google Scholar
• Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med. 2004;351(14):1409–1418.
   PubMed Web of Science ®Google Scholar
• Martínez-Feito A, Melero J, Mora-Díaz S, et al. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation. Immunobiology. 2016;221(1):40–47.
   PubMed Web of Science ®Google Scholar
• Del-Rey M, Ruiz-Contreras J, Bosque A, et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood. 2006;108(4):1306–1312.
   PubMed Web of Science ®Google Scholar
• Magerus-Chatinet A, Stolzenberg MC, Lanzarotti N, et al. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. J Allergy Clin Immunol. 2013;131(2):486–490.
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia R, Mora S, Lozano-Sanchez G, et al. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation. Pediatr Res. 2015;78(6):603–608.
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng L, Lobito A, et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98(1):47–58.
   PubMed Web of Science ®Google Scholar
• Zhu S, Hsu AP, Vacek MM, et al. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome. Hum Genet. 2006;119(3):284–294.
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Magérus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. J Clin Immunol. 2018;38(5):558–568.
   PubMed Web of Science ®Google Scholar
• Miano M, Cappelli E, Pezzulla A, et al. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10 gene. Br J Haematol. 2019;187(4):502–508.
   PubMed Web of Science ®Google Scholar
• Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419(6905):395–399.
   PubMed Web of Science ®Google Scholar
• Niemela J, Kuehn HS, Kelly C, et al. Caspase-8 Deficiency presenting as late-onset multi-organ lymphocytic infiltration with granulomas in two adult siblings. J Clin Immunol. 2015;35(4):348–355.
   PubMed Web of Science ®Google Scholar
• Lehle AS, Farin HF, Marquardt B, et al. Intestinal inflammation and dysregulated immunity in patients with inherited caspase-8 deficiency. Gastroenterology. 2019;156(1):275–278.
   PubMed Web of Science ®Google Scholar
• Bolze A, Byun M, McDonald D, et al. Whole-exome-sequencing-based discovery of human FADD deficiency. Am J Hum Genet. 2010;87(6):873–881.
   PubMed Web of Science ®Google Scholar
• Singh A, Jindal AK, Joshi V, et al. An updated review on phenocopies of primary immunodeficiency diseases. Genes Dis. 2020;7(1):12–25.
   PubMed Web of Science ®Google Scholar
• Magerus-Chatinet A, Neven B, Stolzenberg MC, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest. 2011;121(1):106–112.
   PubMed Web of Science ®Google Scholar
• Del-Rey MJ, Manzanares J, Bosque A, et al. Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation. Immunobiology. 2007;212(2):73–83.
   PubMed Web of Science ®Google Scholar
• Boggio E, Aricò M, Melensi M, et al. Mutation of FAS, XIAP, and UNC13D genes in a patient with a complex lymphoproliferative phenotype. Pediatrics. 2013;132(4):e1052–e1058.
   PubMed Web of Science ®Google Scholar
• Clementi R, Dagna L, Dianzani U, et al. Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med. 2004;351(14):1419–1424.
   PubMed Web of Science ®Google Scholar
• Calvo KR, Price S, Braylan RC, et al. JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood. 2015;125(18):2753–2758.
   PubMed Web of Science ®Google Scholar
• Meynier S, Rieux-Laucat F. After 95 years, it's time to eRASe JMML. Blood Rev. 2020;(43):100652
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F. What's up in the ALPS. Curr Opin Immunol. 2017;49:79–86.
   PubMed Web of Science ®Google Scholar
• Kuehn HS, Niemela JE, Rangel-Santos A, et al. Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans. Blood. 2013;121(16):3117–3125.
   PubMed Web of Science ®Google Scholar
• Patiroglu T, Haluk Akar H, Gilmour K, et al. A case of XMEN syndrome presented with severe auto-immune disorders mimicking autoimmune lymphoproliferative disease. Clin Immunol. 2015;159(1):58–62.
   PubMed Web of Science ®Google Scholar
• Milner JD, Vogel TP, Forbes L, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125(4):591–599.
   PubMed Web of Science ®Google Scholar
• Nabhani S, Schipp C, Miskin H, et al. STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds. Clin Immunol. 2017;181:32–42.
   PubMed Web of Science ®Google Scholar
• Fabre A, Marchal S, Barlogis V, et al. Clinical aspects of STAT3 gain-of-function germline mutations: a systematic review. J Allergy Clin Immunol Pract. 2019;7(6):1958–1969.
   PubMed Web of Science ®Google Scholar
• Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623–1627.
   PubMed Web of Science ®Google Scholar
• Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–1416.
   PubMed Web of Science ®Google Scholar
• Fernández KS, Antony R, Kumar A. Patients with “ALPS-like phenotype” diagnosed with immune dysregulation due to LRBA deficiency. Pediatr Blood Cancer. 2019;66(3):e27558.
   PubMed Web of Science ®Google Scholar
• Wallace JG, Alosaimi MF, Khayat CD, et al. ITK deficiency presenting as autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2020. DOI:https://doi.org/10.1016/j.jaci.2020.06.019
   Google Scholar
• Schipp C, Schlütermann D, Hönscheid A, et al. EBV negative lymphoma and autoimmune lymphoproliferative syndrome like phenotype extend the clinical spectrum of primary immunodeficiency caused by STK4 deficiency. Front Immunol. 2018;9:2400.
   PubMed Web of Science ®Google Scholar
• Olbrich P, Freeman AF. STAT1 and STAT3 mutations: important lessons for clinical immunologists. Expert Rev Clin Immunol. 2018;14(12):1029–1041.
   PubMed Web of Science ®Google Scholar
• Fieschi C, Dupuis S, Catherinot E, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med. 2003;197(4):527–535.
   PubMed Web of Science ®Google Scholar
• Nabhani S, Ginzel S, Miskin H, et al. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease. Haematologica. 2015;100(9):1189–1198.
   PubMed Web of Science ®Google Scholar
• Barzaghi F, Minniti F, Mauro M, et al. ALPS-like phenotype caused by ADA2 deficiency rescued by allogeneic hematopoietic stem cell transplantation. Front Immunol. 2018;9:2767.
   PubMed Web of Science ®Google Scholar
• Stremenova Spegarova J, Lawless D, Mohamad SMB, et al. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. Blood. 2020;136(9):1055–1066.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105(6):2443–2448.
   PubMed Web of Science ®Google Scholar
• Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98(1):194–200.
   PubMed Web of Science ®Google Scholar
• Dowdell KC, Niemela JE, Price S, et al. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood. 2010;115(25):5164–5169.
   PubMed Web of Science ®Google Scholar
• Bleesing JJH. Sorting out the causes of ALPS. J Pediatr. 2005;147(5):571–574.
   PubMed Web of Science ®Google Scholar
• Dale JK, Price S, Tretler J, et al. Use of rituximab for refractory immune cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Blood. 2007;110(11):1319–1319.
   Web of Science ®Google Scholar
• Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood. 2011;118(22):5741–5751.
   PubMed Web of Science ®Google Scholar
• Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol. 2009;146(1):120–122.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009;145(5):569–580.
   PubMed Web of Science ®Google Scholar
• Barrett D, Brown VI, Grupp SA, et al. Targeting the PI3KAKTmTOR signaling axis in children with hematologic malignancies. Paediatr Drugs. 2012;14:299–316.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Jubelirer T, Baluarte HJ, et al. Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant. Pediatr Blood Cancer. 2009;53(6):1114–1116.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145(1):101–106.
   PubMed Web of Science ®Google Scholar
• Rao VK. Approaches to managing autoimmune cytopenias in novel immunological disorders with genetic underpinnings like autoimmune lymphoproliferative syndrome. Front Pediatr. 2015;3:65.
   PubMed Web of Science ®Google Scholar
• Vignesh P, Rawat A, Singh S. An update on the use of immunomodulators in primary immunodeficiencies. Clin Rev Allergy Immunol. 2017;52(2):287–303.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Spaan AN, Neven B, et al. Autoimmune lymphoproliferative syndrome presenting with invasive Streptococcus pneumoniae infection. J Clin Immunol. 2020;40(3):543–546.
   PubMed Web of Science ®Google Scholar
• Forbes LR, Vogel TP, Cooper MA, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665–1669.
   PubMed Web of Science ®Google Scholar
• Lo B, Zhang K, Lu W, et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436–440.
   PubMed Web of Science ®Google Scholar
• Delmonte OM, Castagnoli R, Calzoni E, et al. Inborn errors of immunity with immune dysregulation: from bench to bedside. Front Pediatr. 2019;(7):353.
   PubMed Web of Science ®Google Scholar
• Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35–e40.
   PubMed Web of Science ®Google Scholar
• Rensing-Ehl A, Janda A, Lorenz MR, et al. Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia. Haematologica. 2013;98(12):1948–1955.
   PubMed Web of Science ®Google Scholar
• Sriram S, Joshi AY, Rodriguez V, et al. Autoimmune lymphoproliferative syndrome: a rare cause of disappearing HDL syndrome. Case Reports Immunol. 2016;2016:7945953–7945954.
   PubMed Web of Science ®Google Scholar
• Moraitis AG, Freeman LA, Shamburek RD, et al. Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency. J Clin Lipidol. 2015;9(1):81–90.
   PubMed Web of Science ®Google Scholar
• Caminha I, Fleisher TA, Hornung RL, et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2010;125(4):946–949.e6.
   PubMed Web of Science ®Google Scholar
• Rensing-Ehl A, Warnatz K, Fuchs S, et al. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency. Clin Immunol. 2010;137(3):357–365.
   PubMed Web of Science ®Google Scholar
• Meyts I, Bosch B, Bolze A, et al. Exome and genome sequencing for inborn errors of immunity. J Allergy Clin Immunol. 2016;138(4):957–969.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet. 1999;64(4):1002–1014.
   PubMed Web of Science ®Google Scholar
• Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 2000;288(5475):2354–2357.
   PubMed Web of Science ®Google Scholar
• Kuehn HS, Caminha I, Niemela JE, et al. FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome. J Immunol. 2011;186(10):6035–6043.
   PubMed Web of Science ®Google Scholar
• Bousfiha A, Jeddane L, Al-Herz W, et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015;35(8):727–738.
   PubMed Web of Science ®Google Scholar
• Nabhani S, Hönscheid A, Oommen PT, et al. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome. Clin Immunol. 2014;155(2):231–237.
   PubMed Web of Science ®Google Scholar
• Sobh A, Crestani E, Cangemi B, et al. Autoimmune lymphoproliferative syndrome caused by a homozygous FasL mutation that disrupts FasL assembly. J Allergy Clin Immunol. 2016;137(1):324–327.
   PubMed Web of Science ®Google Scholar
• Bisgin A, Boga I, Yilmaz M, et al. The utility of next-generation sequencing for primary immunodeficiency disorders: experience from a clinical diagnostic laboratory. Biomed Res Int. 2018;2018:9647253.
   PubMed Web of Science ®Google Scholar
• Magerus-Chatinet A, Rieux-Laucat F. In vitro evaluation of the apoptosis function in human activated T cells. Methods Mol Biol. 2017;1557:33–40.
   PubMedGoogle Scholar
• Lo B, Ramaswamy M, Davis J, et al. A rapid ex vivo clinical diagnostic assay for Fas receptor-induced T lymphocyte apoptosis. J Clin Immunol. 2013;33(2):479–488.
   PubMed Web of Science ®Google Scholar
• Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol. 2008;66(1):52–64.
   PubMed Web of Science ®Google Scholar
• Mateo V, Ménager M, De Saint-Basile G, et al. Perforin-dependent apoptosis functionally compensates Fas deficiency in activation-induced cell death of human T lymphocytes. Blood. 2007;110(13):4285–4292.
   PubMed Web of Science ®Google Scholar
• Muppidi J, Porter M, Siegel RM. Measurement of apoptosis and other forms of cell death. Curr Protoc Immunol. 2004;59:3.17.1–3.17.36.
   PubMedGoogle Scholar
• Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta + T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood. 2009;113(13):3027–3030.
   PubMed Web of Science ®Google Scholar
• Cabral-Marques O, Schimke LF, de Oliveira EB, et al. Flow cytometry contributions for the diagnosis and immunopathological characterization of primary immunodeficiency diseases with immune dysregulation. Front Immunol. 2019;(10):2742.
   PubMed Web of Science ®Google Scholar
• Hsu AP, Dowdell KC, Davis J, et al. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance. Genet Med. 2012;14(1):81–89.
   PubMed Web of Science ®Google Scholar
• Krammer PH, Weyd H. Life, death and tolerance. Biochem Biophys Res Commun. 2017;482(3):470–472.
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Fischer A, Le Deist F. Cell-death signaling and human disease. Curr Opin Immunol. 2003;15(3):325–331.
   PubMed Web of Science ®Google Scholar
• Hauck F, Magerus-Chatinet A, Vicca S, et al. Somatic loss of heterozygosity, but not haploinsufficiency alone, leads to full-blown autoimmune lymphoproliferative syndrome in 1 of 12 family members with FAS start codon mutation. Clin Immunol. 2013;147(1):61–68.
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Casamova JL. Immunology. Autoimmunity by haploinsufficiency. Science. 2014;345(6204):1560–1561.
   PubMed Web of Science ®Google Scholar